Meta-Analysis
Copyright ©The Author(s) 2024.
World J Gastrointest Oncol. Aug 15, 2024; 16(8): 3672-3686
Published online Aug 15, 2024. doi: 10.4251/wjgo.v16.i8.3672
Figure 1
Figure 1 Flow diagram. RCTs: Randomized controlled trials.
Figure 2
Figure 2 Network graph of the outcomes. A: Network graph of overall survival; B: Network graph of progression-free survival; C: Network graph of complete response, partial response, objective response rate, and disease control rate; D: Network graph of any grades adverse events (AEs); E: Network graph of 3-4 grades AEs; F: Network graph of 3-4 grades AEs for thrombocytopenia; G: Network graph of 3-4 grades AEs for elevated total bilirubin. HAIC: Hepatic arterial infusion chemotherapy; Sora: Sorafenib; Lenv: Lenvatinib; TACE: Transarterial chemoembolization; RT: Radiotherapy; S-1: A composite preparation of a 5-fluorouracil prodrug; A: Ablation; PD-1: Programmed death 1.
Figure 3
Figure 3 Forest plot of the outcomes and P score for treatment ranking. A: Forest plot of overall survival; B: Forest plot of progression-free survival; C: Forest plot of complete response; D: Forest plot of partial response; E: Forest plot of objective response rate; F: Forest plot of disease control rate; G: Forest plot of any grades adverse events (AEs); H: Forest plot of 3-4 grades AEs; I: Forest plot of 3-4 grades AEs for thrombocytopenia; J: Forest plot of 3-4 grades AEs for elevated total bilirubin. HAIC: Hepatic arterial infusion chemotherapy; Sora: Sorafenib; Lenv: Lenvatinib; TACE: Transarterial chemoembolization; RT: Radiotherapy; S-1: A composite preparation of a 5-fluorouracil prodrug; A: Ablation; PD-1: Programmed death 1.